Scientists have developed a new technique to analyze circulating tumor DNA (ctDNA) in patients with metastatic cancer, offering a less invasive way to monitor disease progression. This method allows for the detection of tumor-specific genetic material in the bloodstream, providing valuable insights into how cancer evolves and responds to treatment. By identifying mutations and resistance mechanisms early, doctors can adjust therapies in real time, improving patient outcomes.
This advancement in ctDNA analysis could revolutionize cancer care by reducing the need for repeated biopsies and offering a more accessible monitoring tool. The technique enhances precision oncology, enabling more personalized treatment strategies based on a patient’s unique tumor profile. As research continues, this approach has the potential to become a standard method for tracking metastatic cancer, leading to more effective and timely interventions. Click for More Details
